{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:16:21Z","timestamp":1778598981328,"version":"3.51.4"},"reference-count":39,"publisher":"BMJ","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Stroke Vasc Neurol"],"accepted":{"date-parts":[[2026,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Limited evidence is available regarding rates of vascular events and mortality associated with an initial and a recurrent ischaemic stroke (IS) in people with non-cardioembolic IS (NCIS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This study evaluated rates of clinical events and antithrombotic therapy among people with NCIS or transient ischaemic attack (TIA), and subsequent event rates after a first recurrent IS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with a first hospitalisation for NCIS or TIA between 1 January 2015 and 29 October 2022 were identified in a Japanese nationwide hospital database (N=18\u2009719). NCIS was identified based on diagnostic codes. Clinical events were assessed after discharge of the initial and the first recurrent IS hospitalisations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Rates (per 1000 person-years (95% CIs)) of IS, death, haemorrhagic stroke, myocardial infarction or unstable angina, major bleeding, and newly diagnosed atrial fibrillation were 103.5 (100.0 to 107.0), 45.9 (43.8 to 48.1), 10.6 (9.6 to 11.7), 21.7 (20.2 to 23.2), 60.0 (57.4 to 62.5) and 22.9 (21.3 to 24.4), respectively. In the subcohort with a first recurrent IS (N=3081), rates of these events were 199.9 (186.6 to 213.1), 53.3 (46.5 to 60.2), 15.6 (11.9 to 19.4), 39.6 (33.5 to 45.6), 96.5 (87.1 to 105.9) and 52.7 (45.7 to 59.8), respectively, following the recurrent IS. Following the initial hospitalisation, antiplatelet therapy was used in 71.8% of people. However, only 54.2% of people were prescribed any antithrombotic therapy in the 90 days prior to the first recurrent IS, which increased to 77.0% after the event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The rate of recurrent IS was high in people with NCIS and more effective, tolerable prevention strategies are needed. The high rate of clinical events following a first recurrent IS may underscore the importance of preventing IS recurrence in people with NCIS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/svn-2025-004725","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:50:20Z","timestamp":1778597420000},"page":"svn-2025-004725","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic therapy, vascular events and mortality after non-cardioembolic ischaemic stroke: a nationwide hospital-based cohort study in Japan"],"prefix":"10.1136","author":[{"given":"Teruyuki","family":"Hirano","sequence":"first","affiliation":[{"name":"Department of Stroke and Cerebrovascular Medicine, Kyorin University School of Medicine, Mitaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4402-0209","authenticated-orcid":false,"given":"Suguru","family":"Okami","sequence":"additional","affiliation":[{"name":"Medical Affairs & Pharmacovigilance, Bayer Yakuhin Kabushiki Kaisha, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryu","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Kyushu Daigaku Igakubu Daigakuin Igakukei Gakufu Daigakuin Igaku Kenkyuin, Fukuoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coralie","family":"Lecomte","sequence":"additional","affiliation":[{"name":"Aetion Inc, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Yucuma","sequence":"additional","affiliation":[{"name":"Aetion Iberia, SL, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Takeichi","sequence":"additional","affiliation":[{"name":"Medical Affairs & Pharmacovigilance, Bayer Yakuhin Kabushiki Kaisha, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsubasa","family":"Tajima","sequence":"additional","affiliation":[{"name":"Medical Affairs & Pharmacovigilance, Bayer Yakuhin Kabushiki Kaisha, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Bamber","sequence":"additional","affiliation":[{"name":"Bayer AG, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Xeni","sequence":"additional","affiliation":[{"name":"Bayer Inc, Mississauga, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Karlsdotter","sequence":"additional","affiliation":[{"name":"Bayer Hispania, SLU, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukul","family":"Sharma","sequence":"additional","affiliation":[{"name":"McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2026051207501182000_svn-2025-004725v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00252-0"},{"key":"2026051207501182000_svn-2025-004725v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00369-7"},{"key":"2026051207501182000_svn-2025-004725v1.3","first-page":"e137","article-title":"Global Burden, Risk Factor Analysis, and Prediction Study of Ischemic Stroke, 1990-2030","volume":"101","author":"Fan","year":"2023","journal-title":"Neurology (ECronicon)"},{"key":"2026051207501182000_svn-2025-004725v1.4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2396987318797245","article-title":"Non-cardioembolic stroke\/transient ischaemic attack in Asians and non-Asians: a post-hoc analysis of the PERFORM study","volume":"4","author":"Hoshino","year":"2019","journal-title":"Eur Stroke J"},{"key":"2026051207501182000_svn-2025-004725v1.5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.038166"},{"key":"2026051207501182000_svn-2025-004725v1.6","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/17474930221090347","article-title":"Japan Stroke Society Guideline 2021 for the Treatment of Stroke","volume":"17","author":"Miyamoto","year":"2022","journal-title":"Int J Stroke"},{"key":"2026051207501182000_svn-2025-004725v1.7","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/17512433.2022.2118713","article-title":"Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack","volume":"15","author":"Scalia","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026051207501182000_svn-2025-004725v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70274-X"},{"key":"2026051207501182000_svn-2025-004725v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.12.010"},{"key":"2026051207501182000_svn-2025-004725v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70092-3"},{"key":"2026051207501182000_svn-2025-004725v1.11","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.013540"},{"key":"2026051207501182000_svn-2025-004725v1.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800410"},{"key":"2026051207501182000_svn-2025-004725v1.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215340"},{"key":"2026051207501182000_svn-2025-004725v1.14","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000375"},{"key":"2026051207501182000_svn-2025-004725v1.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916870"},{"key":"2026051207501182000_svn-2025-004725v1.16","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(19)30148-6"},{"key":"2026051207501182000_svn-2025-004725v1.17","unstructured":"ClinicalTrials.gov . A study to test asundexian for preventing a stroke caused by a clot in participants after an acute ischemic stroke or after a high-risk transient ischemic attack. Available: https:\/\/clinicaltrials.gov\/study\/NCT05686070 [Accessed 8 May 2025]."},{"key":"2026051207501182000_svn-2025-004725v1.18","unstructured":"ClinicalTrials.gov . A study of milvexian in participants after an acute ischemic stroke or high-risk transient ischemic attack- librexia-stroke (librexia-strok). 2025. Available: https:\/\/www.clinicaltrials.gov\/study\/NCT05702034"},{"key":"2026051207501182000_svn-2025-004725v1.19","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.5551\/jat.63344","article-title":"Long-term trends in the 5-year risk of recurrent stroke over a half century in a Japanese community: the Hisayama Study","volume":"29","author":"Nakanishi","year":"2022","journal-title":"J Atheroscler Thromb"},{"key":"2026051207501182000_svn-2025-004725v1.20","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1253\/circj.CJ-20-0024","article-title":"Two-year recurrence after first-ever stroke in a general population of 1.4 million Japanese patients - the Shiga Stroke and Heart Attack Registry Study","volume":"84","author":"Takashima","year":"2020","journal-title":"Circ J"},{"key":"2026051207501182000_svn-2025-004725v1.21","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13195744","article-title":"Recurrent ischemic stroke and transient ischemic attack: risk of single and multiple recurrence","volume":"13","author":"Park","year":"2024","journal-title":"J Clin Med"},{"key":"2026051207501182000_svn-2025-004725v1.22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/bc.bc_73_22","article-title":"Risk factors for multiple recurrent ischemic strokes","volume":"9","author":"Uzuner","year":"2023","journal-title":"Brain Circ"},{"key":"2026051207501182000_svn-2025-004725v1.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"key":"2026051207501182000_svn-2025-004725v1.24","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1253\/circj.CJ-19-0089","article-title":"Development of quality indicators of stroke centers and feasibility of their measurement using a nationwide insurance claims database in Japan \u2013 J-ASPECT Study","volume":"83","author":"Nishimura","year":"2019","journal-title":"Circ J"},{"key":"2026051207501182000_svn-2025-004725v1.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70310-7"},{"key":"2026051207501182000_svn-2025-004725v1.26","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamaneurol.2019.0591","article-title":"Tailoring the approach to embolic stroke of undetermined source: a review","volume":"76","author":"Kamel","year":"2019","journal-title":"JAMA Neurol"},{"key":"2026051207501182000_svn-2025-004725v1.27","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1212\/WNL.39.9.1246","article-title":"Intracranial branch atheromatous disease: a neglected, understudied, and underused concept","volume":"39","author":"Caplan","year":"1989","journal-title":"Neurology (ECronicon)"},{"key":"2026051207501182000_svn-2025-004725v1.28","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1177\/1747493019852177","article-title":"Branch atheromatous disease diagnosed as embolic stroke of undetermined source: a sub-analysis of NAVIGATE ESUS","volume":"14","author":"Uchiyama","year":"2019","journal-title":"Int J Stroke"},{"key":"2026051207501182000_svn-2025-004725v1.29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.5093"},{"key":"2026051207501182000_svn-2025-004725v1.30","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100651","article-title":"Risk of recurrent stroke in Rotterdam between 1990 and 2020: a population-based cohort study","volume":"30","author":"Berghout","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026051207501182000_svn-2025-004725v1.31","doi-asserted-by":"crossref","first-page":"336","DOI":"10.5853\/jos.2020.00325","article-title":"Long-term survival after stroke in 1.4 million Japanese population: Shiga Stroke and Heart Attack Registry","volume":"22","author":"Takashima","year":"2020","journal-title":"J Stroke"},{"key":"2026051207501182000_svn-2025-004725v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60834-3"},{"key":"2026051207501182000_svn-2025-004725v1.33","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.31.2.456"},{"key":"2026051207501182000_svn-2025-004725v1.34","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.108.521419"},{"key":"2026051207501182000_svn-2025-004725v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(19)30369-2"},{"key":"2026051207501182000_svn-2025-004725v1.36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000365732","article-title":"Discontinuation of antiplatelet treatment and risk of recurrent stroke and all-cause death: a cohort study","volume":"43","author":"Ostergaard","year":"2014","journal-title":"Neuroepidemiology"},{"key":"2026051207501182000_svn-2025-004725v1.37","doi-asserted-by":"publisher","DOI":"10.1159\/000351144"},{"key":"2026051207501182000_svn-2025-004725v1.38","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1080\/14656566.2024.2404108","article-title":"Evolution of antiplatelet therapy in Japan for the management of cerebrovascular and cardiovascular disease: a survey using data from an insurance claims data information service","volume":"25","author":"Miyake","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"2026051207501182000_svn-2025-004725v1.39","first-page":"623","article-title":"(New grading of level of disordered consiousness [author\u2019s translation])","volume":"2","author":"Ohta","year":"1974","journal-title":"No Shinkei Geka"}],"container-title":["Stroke and Vascular Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/svn-2025-004725","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:50:27Z","timestamp":1778597427000},"score":1,"resource":{"primary":{"URL":"https:\/\/svn.bmj.com\/lookup\/doi\/10.1136\/svn-2025-004725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":39,"alternative-id":["10.1136\/svn-2025-004725"],"URL":"https:\/\/doi.org\/10.1136\/svn-2025-004725","relation":{},"ISSN":["2059-8688","2059-8696"],"issn-type":[{"value":"2059-8688","type":"print"},{"value":"2059-8696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]}}}